BioHarvest Sciences (NASDAQ:BHST) Raised to Hold at Wall Street Zen

BioHarvest Sciences (NASDAQ:BHST) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioHarvest Sciences in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioHarvest Sciences has an average rating of “Moderate Buy” and an average price target of $13.67.

BioHarvest Sciences Trading Down 3.9%

Shares of BHST opened at $11.05 on Friday. The firm’s fifty day simple moving average is $9.45 and its two-hundred day simple moving average is $7.65. BioHarvest Sciences has a 12 month low of $4.66 and a 12 month high of $12.80. The stock has a market capitalization of $181.44 million, a P/E ratio of -15.79 and a beta of 0.78.

BioHarvest Sciences (NASDAQ:BHST) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million during the quarter, compared to analyst estimates of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. As a group, research analysts predict that BioHarvest Sciences will post -0.8 EPS for the current fiscal year.

Institutional Trading of BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC grew its stake in BioHarvest Sciences Inc. (NASDAQ:BHST) by 7.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,391 shares of the company’s stock after purchasing an additional 3,120 shares during the quarter. True North Advisors LLC owned approximately 0.27% of BioHarvest Sciences worth $275,000 at the end of the most recent reporting period.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.